Other anti-MET mAbs in development are YYB - 101 (YooYoung Pharmaceutical Co, Seoul, Korea), a humanized rabbit anti-HGF antibody currently being tested in an ongoing phase I trial in patients with advanced solid tumors (NCT02499224)
Unregulated BPC-157 products pose risks including contamination, incorrect dosages, and unknown interactions with prescribed medications
This section will guide you through the critical considerations and questions to discuss with your healthcare provider
This process is vital for maintaining liver health and overall well-being
Better lipid profiles mean less plaque formation, less arterial inflammation, and lower risk of the cardiovascular events that kill millions each year
Is sublingual GLP-1 as effective as the injectable version